<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBM</journal-id><journal-title-group><journal-title>Journal of Biosciences and Medicines</journal-title></journal-title-group><issn pub-type="epub">2327-5081</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbm.2021.91010</article-id><article-id pub-id-type="publisher-id">JBM-106829</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Glutathione Reductase, Liver Transaminases and Atypical Lymphocytes Count as Early Predictive Biomarkers in Diagnosis of Thrombocytopenia in Dengue Viral Infection
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samantha</surname><given-names>Bandara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lal</surname><given-names>G. Chandrasena</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hemantha</surname><given-names>Peiris</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Visula</surname><given-names>Abesuriya</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Arjuna</surname><given-names>De Silva</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chandima</surname><given-names>De Mel</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sanjay</surname><given-names>De Mel</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Suranjith</surname><given-names>L. Seneviratne</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka</addr-line></aff><aff id="aff6"><addr-line>Institute of Immunity and Transplantation, Royal Free Hospital and University College, London, UK</addr-line></aff><aff id="aff5"><addr-line>Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore</addr-line></aff><aff id="aff2"><addr-line>Nawaloka Hospitals Research and Education Foundation, Nawaloka Hospitals PLC, Colombo, Sri Lanka</addr-line></aff><aff id="aff1"><addr-line>Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, University of Sri Jayewardenepura, Nugegoda, Sri Lanka</addr-line></aff><aff id="aff4"><addr-line>Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>01</month><year>2021</year></pub-date><volume>09</volume><issue>01</issue><fpage>119</fpage><lpage>130</lpage><history><date date-type="received"><day>3,</day>	<month>December</month>	<year>2020</year></date><date date-type="rev-recd"><day>25,</day>	<month>January</month>	<year>2021</year>	</date><date date-type="accepted"><day>28,</day>	<month>January</month>	<year>2021</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective: The aim of the study is to identify whether Atypical Lymphocyte (AL), liver transaminases, and Glutathione Reductase (GR) can be used as potential biomarkers in the assessment of severity and thrombocytopenia in dengue. 
  Methods: A cross-sectional analytical study was carried out on diagnosed dengue patients admitted to Nawaloka Hospital, Sri Lanka. Blood samples were taken from patients (n = 50) on the day of admission, 3
  <sup>rd</sup> and 5
  <sup>th</sup> day from admission for analysis of GR, aspartate transaminase, alanine transaminase, platelets, white blood cells, and Atypical Lymphocytes (AL). 
  Results: GR level of all three measured stages had a higher area under the curve (&gt;88%), high sensitivity and specificity compared to liver transaminases. A significant regression model represents on admission GR and AL levels as predictive variables to platelet levels in day 03 from admission (Day 3 Platelet level = 127155.3 - 383 * GR - 0.431 * AL). 
  Conclusion: Liver transaminases, GR, and AL% can be considered as a profile of predictive biomarkers in early diagnosis of severity of dengue infection. The degree of thrombocytopenia can be predicted using on admission GR and AL% level in acute dengue viral infection.
 
</p></abstract><kwd-group><kwd>Dengue</kwd><kwd> Liver Transaminases</kwd><kwd> Glutathione Reductase</kwd><kwd> Atypical Lymphocytes</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Dengue is a mosquito-borne viral disease, extent in many tropical and subtropical regions in the world. A recent estimate indicates more than 390 million dengue infections with 96 million manifests clinically [<xref ref-type="bibr" rid="scirp.106829-ref1">1</xref>]. Dengue virus belongs to family Flaviviridae consisting of four different antigenic serotypes [<xref ref-type="bibr" rid="scirp.106829-ref2">2</xref>]. Dengue virus causes Dengue Fever (DF) with the most severe and life-threatening forms being Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) [<xref ref-type="bibr" rid="scirp.106829-ref3">3</xref>].</p><p>Dengue Fever is diagnosed by several laboratory methods and clinical symptoms. The most used laboratory methods are virus isolation, detection of viral RNA, detection of Nonstructural Protein1 (NS1) antigens and antibody detection (IgG and IgM) [<xref ref-type="bibr" rid="scirp.106829-ref4">4</xref>]. World Health Organization criteria classify dengue according to levels of severity as dengue without warning signs, dengue with warning signs (abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, liver enlargement, increasing hematocrit with decreasing platelets), and severe dengue (dengue with severe plasma leakage, severe bleeding, or organ failure) [<xref ref-type="bibr" rid="scirp.106829-ref5">5</xref>]. All of above-mentioned laboratory methods and clinical classifications are only to diagnose dengue fever and not predicting the severity of the disease.</p><p>Studies have reported several biomarkers such as serum lactate dehydrogenase, creatine kinase, and albumin levels at 48 - 96 hours after onset of fever to predict severity acute dengue fever [<xref ref-type="bibr" rid="scirp.106829-ref6">6</xref>]. Timely assessment of liver transaminases was also identified as a predictive indicator of the severity of dengue fever [<xref ref-type="bibr" rid="scirp.106829-ref7">7</xref>]. A consistent high serum chymase level also reported as a predictive marker of dengue hemorrhagic fever [<xref ref-type="bibr" rid="scirp.106829-ref8">8</xref>].</p><p>Experimental fact of immune pathology is a fundamental requirement in elucidating of severe dengue fever [<xref ref-type="bibr" rid="scirp.106829-ref9">9</xref>]. Both innate and acquired immune responses are also identified as predictive markers in dengue fever. The primary response against dengue infection is the internalization of the pathogen by an overwhelming number of immune cells and the production of antibodies. Atypical lymphocytes (CD19+ B lymphocytes) are antibody immune reactions to the dengue virus, which significantly increase in anti-dengue IgG antibodies during the secondary dengue infection. Increased proportion of atypical plasmacytoid lymphocytes have also been described in patients with dengue infection [<xref ref-type="bibr" rid="scirp.106829-ref10">10</xref>]. Atypical Lymphocytes (AL) and CD19+ cell counts have been identified as useful diagnostic tools for identification of the severity of dengue infection and the recovery from the disease [<xref ref-type="bibr" rid="scirp.106829-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref12">12</xref>]. On admission AL count has proposed as a negative predictive factor for severe thrombocytopenia in day 5 day 7 of dengue fever [<xref ref-type="bibr" rid="scirp.106829-ref13">13</xref>].</p><p>Dengue virus generates oxidative stress through the effect of NADPH oxidase. This triggers the inflammatory cytokine response, contributing to the pathogenesis of dengue viral infection [<xref ref-type="bibr" rid="scirp.106829-ref14">14</xref>]. Thus the antioxidants play a crucial role in host defense against dengue viral infection [<xref ref-type="bibr" rid="scirp.106829-ref15">15</xref>]. Increased level levels of Superoxide Dismutase (SOD), Malondialdehyde (MDA), and Nitric Oxide (NO), and decreased levels of Trolox equivalent antioxidant capacity in plasma, serum paraoxonase, erythrocyte glutathione, and Glutathione Peroxidase (GPx) activities have been reported as useful biomarkers of dengue infection [<xref ref-type="bibr" rid="scirp.106829-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref17">17</xref>].</p><p>Hepatic dysfunction is a well-recognized feature of dengue infections, often demonstrated by hepatomegaly and mild to moderate increases in transaminase levels [<xref ref-type="bibr" rid="scirp.106829-ref18">18</xref>]. The dengue associated liver injury can be both viral induced or immune mediated. This has been shown in dengue virus infected hepatocytes in mouse models [<xref ref-type="bibr" rid="scirp.106829-ref19">19</xref>].</p><p>Glutathione Reductase (GR) is one of the antioxidant enzymes, which is directly responsible in maintaining of reduced glutathione level by recycling of oxidized glutathione [<xref ref-type="bibr" rid="scirp.106829-ref20">20</xref>]. Serum Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) are most commonly used markers to monitor acute liver injury. Therefore, present study assessed the longitudinal changes (on admission, 3<sup>rd</sup> day from admission and 5<sup>th</sup> day from admission) of AL, GR, AST and ALT as predictive indicators of severity and thrombocytopenia in dengue viral infection. Currently, there is no valid laboratory test available to predict the severity of dengue infection. Therefore, the present study has been identified whether these biomarkers can be used as potential biomarkers in the assessment of severity and thrombocytopenia in dengue viral infection.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>A cross sectional analytical study was carried out on dengue patients admitted to Nawaloka Hospital (NH), Sri Lanka, from January to August 2019.</p><sec id="s2_1"><title>2.1. Ethical Approval</title><p>Ethical approval for the study was obtained from the Ethics Review Committee (Reference Number: NHREF/9/18), Nawaloka Hospitals, Colombo 02, Sri Lanka. Informed written consent was obtained from each the patient or by parent/guardian prior to sampling.</p></sec><sec id="s2_2"><title>2.2. Study Sample</title><p>A hospital-based study was carried out with 50 patients (Male-29, Female-21), age 12 years and above positive for dengue antigen NS1 (SD BIOLINE Dengue NS1 kit, Standard Diagnostics, Gyeonggi, South Korea) and admitted at medical units at Nawaloka Hospital, Colombo, Sri Lanka.</p></sec><sec id="s2_3"><title>2.3. Data Collection</title><p>Venous blood samples (5 ml) were collected from patients on admission, 3<sup>rd</sup> day from admission and 5<sup>th</sup> day from admission for analysis of laboratory parameters such as AST, ALT, GR levels, platelet, and white blood cells count. The clinical parameters such as presenting symptoms, vital signs and dengue warning signs were recorded throughout the study period.</p></sec><sec id="s2_4"><title>2.4. Sample Analysis</title><p>Blood samples were collected into lithium heparin tubes and separated serum was immediately stored in aliquot at −20˚C. GR antioxidants concentrations were determined by Randox commercial assay kit (Ransel test kit, Randox Laboratories, UK) on Dimension clinical chemistry analyzer (Germany). The serum sample was used to detect AST and ALT (Cobas, Germany) by the Cobas clinical chemistry analyzer (Roche, Germany). The blood samples collected into EDTA tubes were used to assess the full blood count using the Sysmex haematology analyzer (XS500i, Japan).</p><p>The dengue severity levels of patients were categorized according to 2009 WHO criteria [<xref ref-type="bibr" rid="scirp.106829-ref5">5</xref>].</p></sec><sec id="s2_5"><title>2.5. Statistics</title><p>The statistical analysis was performed using SPSS version 25.0. Descriptive statistics were given as measures of central tendency and frequencies. The Shapiro-Wilk test was performed to test the normal distribution. Paired sample t-test or Wilcoxon signed rank test was used to determine any statistically significant differences of biochemical parameters between admission days. Pearson correlation coefficients (r) were used to analyze the associations between AL% with GSH, AST and ALT. Receiver Operating Characteristic (ROC) analysis was used to obtain sensitivity, specificity and cut of values of GR, AST and ALT levels to predict severity of dengue fever in relation to AL%. A linear regression model was developed to predict platelet level in 03<sup>rd</sup> day from admission by using on admission GR and AL%. Statistical significance was defined as p &lt; 0 05.</p></sec></sec><sec id="s3"><title>3. Results</title><p>The study recruited 50 patients (male—29 and female—21, average age 31.6 &#177; 13.5 years), who were confirmed as having Dengue fever by rapid immunochromatography test (NS1). All of the patients were admitted on day 03 of fever. The clinical symptoms of patients recorded on admission are depicted in <xref ref-type="table" rid="table1">Table 1</xref>. A significantly high percentage of patients were recorded body pain (100%) and headache (83.3%) on admission.</p><p><xref ref-type="table" rid="table2">Table 2</xref> shows GR, ALT, AST, AL, platelet count and total white blood cell (WBC) count of dengue patients. There were statistically significant differences of all parameters on admission, day 3, and day 5 from admission. Although these parameters were significant, GR, AST, ALT levels were observed very high on 3<sup>rd</sup> day from admission compared to day 0 and day 5. The highest AL% was observed on admission.</p><p>However, results showed that the test values of day 3 from admission were significantly higher than the rest of the days indicating that day 3 from admission is appeared to be very important as far as clinical management of patients is concerned.</p><p>Furthermore, the Pearson correlation showed a significant positive coefficient of AL% with GR, AST, and ALT in the respective days of admission (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical signs and symptoms of DF patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Yes</th><th align="center" valign="middle" >No</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Clinical symptoms</td></tr><tr><td align="center" valign="middle" >Nausea</td><td align="center" valign="middle" >41%</td><td align="center" valign="middle" >59%</td></tr><tr><td align="center" valign="middle" >Headache</td><td align="center" valign="middle" >83.3%</td><td align="center" valign="middle" >16.7%</td></tr><tr><td align="center" valign="middle" >Retro orbital pain</td><td align="center" valign="middle" >25%</td><td align="center" valign="middle" >75%</td></tr><tr><td align="center" valign="middle" >Abdominal pain</td><td align="center" valign="middle" >11.4%</td><td align="center" valign="middle" >88.6%</td></tr><tr><td align="center" valign="middle" >Arthralgia Myalgia</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >0%</td></tr><tr><td align="center" valign="middle" >Restless</td><td align="center" valign="middle" >11.9%</td><td align="center" valign="middle" >88.1%</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Clinical signs</td></tr><tr><td align="center" valign="middle" >Macular skin rash</td><td align="center" valign="middle" >8.9%</td><td align="center" valign="middle" >91.1%</td></tr><tr><td align="center" valign="middle" >Petechial rash</td><td align="center" valign="middle" >11.9%</td><td align="center" valign="middle" >88.1%</td></tr><tr><td align="center" valign="middle" >Vomiting</td><td align="center" valign="middle" >11.1%</td><td align="center" valign="middle" >88.9%</td></tr><tr><td align="center" valign="middle" >Haematemesis</td><td align="center" valign="middle" >11.1%</td><td align="center" valign="middle" >88.9%</td></tr><tr><td align="center" valign="middle" >Melena</td><td align="center" valign="middle" >11.6%</td><td align="center" valign="middle" >88.4%</td></tr><tr><td align="center" valign="middle" >Diarrhea</td><td align="center" valign="middle" >35.6%</td><td align="center" valign="middle" >64.4%</td></tr><tr><td align="center" valign="middle" >Bleeding Manifestation</td><td align="center" valign="middle" >11.6%</td><td align="center" valign="middle" >88.4%</td></tr><tr><td align="center" valign="middle" >RHS tenderness</td><td align="center" valign="middle" >47.6%</td><td align="center" valign="middle" >52.1%</td></tr><tr><td align="center" valign="middle" >Epigastric Tenderness</td><td align="center" valign="middle" >20.8%</td><td align="center" valign="middle" >79.2%</td></tr><tr><td align="center" valign="middle" >Hepatomegaly</td><td align="center" valign="middle" >10.4%</td><td align="center" valign="middle" >89.6%</td></tr><tr><td align="center" valign="middle" >Respi. Distress</td><td align="center" valign="middle" >10.4%</td><td align="center" valign="middle" >89.6%</td></tr><tr><td align="center" valign="middle" >Petechiae</td><td align="center" valign="middle" >10.4%</td><td align="center" valign="middle" >89.6%</td></tr><tr><td align="center" valign="middle" >Impaired conscious</td><td align="center" valign="middle" >10.9%</td><td align="center" valign="middle" >89.1%</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Summary table of biochemical and haematological parameters of patients</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >On admission (Mean &#177; SD)</th><th align="center" valign="middle" >3<sup>rd</sup> day from the admission (Mean &#177; SD)</th><th align="center" valign="middle" >05<sup>th</sup> day from the admission (Mean &#177; SD)</th></tr></thead><tr><td align="center" valign="middle" >ALT (IU/L)</td><td align="center" valign="middle" >68.5 &#177; 47.6<sup> </sup></td><td align="center" valign="middle" >125.9 &#177; 133.0*<sup> </sup></td><td align="center" valign="middle" >91.8 &#177; 89.8<sup> </sup></td></tr><tr><td align="center" valign="middle" >AST (IU/L)</td><td align="center" valign="middle" >71.2 &#177; 58.2<sup> </sup></td><td align="center" valign="middle" >144.2 &#177; 144.8*<sup> </sup></td><td align="center" valign="middle" >93.8 &#177; 71.7<sup> </sup></td></tr><tr><td align="center" valign="middle" >GR (U/L)</td><td align="center" valign="middle" >100.9 &#177; 25.5<sup> </sup></td><td align="center" valign="middle" >130.2 &#177;35.1*<sup> </sup></td><td align="center" valign="middle" >119.8 &#177; 29.2<sup> </sup></td></tr><tr><td align="center" valign="middle" >PLT (per &#181;l)</td><td align="center" valign="middle" >97,600 &#177; 33,000<sup> </sup></td><td align="center" valign="middle" >65,100 &#177; 26,500*<sup> </sup></td><td align="center" valign="middle" >85,300 &#177; 21,300<sup> </sup></td></tr><tr><td align="center" valign="middle" >WBC (per &#181;l)</td><td align="center" valign="middle" >2460 &#177; 880<sup> </sup></td><td align="center" valign="middle" >3500 &#177; 1220<sup> </sup></td><td align="center" valign="middle" >4770 &#177; 1770<sup> </sup></td></tr><tr><td align="center" valign="middle" >AL (%)</td><td align="center" valign="middle" >0.64 &#177; 0.35<sup>† </sup></td><td align="center" valign="middle" >0.43 &#177; 0.24<sup> </sup></td><td align="center" valign="middle" >0.30 &#177; 0.18<sup> </sup></td></tr></tbody></table></table-wrap><p>*The values were significantly different (p &lt; 0.05) compared to on admission and day 05 from admission, <sup>†</sup>The values of on admission appeared to be significantly high (p &lt; 0.05) compared to day 03 and day 05 from admission.</p><p>These biochemical markers were also compared with the atypical lymphocyte count on three testing days and the GR, AST and ALT levels were significantly higher (<xref ref-type="table" rid="table3">Table 3</xref>) among dengue patients with on admission atypical lymphocyte count was more than 0.55% [<xref ref-type="bibr" rid="scirp.106829-ref12">12</xref>].</p><p>ROC curves analyze (<xref ref-type="table" rid="table4">Table 4</xref>) using on admission atypical lymphocyte</p><p>count &gt;0.55% as an indicator of the severity of dengue infection, shown that the GR level of all three measured stages had a higher area under the curve (&gt;88%), high sensitivity and specificity compared to liver transaminases.</p><p>Furthermore to the above ROC curves data were reanalyzed to find out whether there is any relationship between the platelet count of day 03 and day 0 values of other parameters by using ROC curves of 03 models (<xref ref-type="fig" rid="fig2">Figure 2</xref>). All of the models of ROC curves had significant areas under the curves &gt; 0.8 with the same cut off value for day 03 platelet levels (69,000/per &#181;l). This indicates the patients on the day admission showed GR, AST, ALT, and AL% levels more than above observed cut-offs (<xref ref-type="table" rid="table4">Table 4</xref>), have been decreased their platelet level less than 69,000 per/&#181;l on day 03 from admission. However, total white blood cell count was not observed significant changes with the above biomarkers.</p><p>In addition, we developed a regression model to predict platelet level on day 03 from admission by using on admission variables GR, AST, ALT, and AL (<xref ref-type="table" rid="table5">Table 5</xref>). A significant regression model represents on admission GR and AL levels as predictive variables to platelet levels in day 03 from admission (Day 03 Platelet level = 127155.3 − 383 * GR − 0.431 * AL).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of AL count &gt;0.55% and GR, AST and ALT levels on admission, day 3 and day 5 from admission</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >GR (IU/L)</th><th align="center" valign="middle"  colspan="2"  >AST (IU/L)</th><th align="center" valign="middle"  colspan="2"  >ALT (IU/L)</th></tr></thead><tr><td align="center" valign="middle" >AL &gt; 0.55% n = 31</td><td align="center" valign="middle" >AL &lt; 0.55% n = 19</td><td align="center" valign="middle" >AL &gt; 0.55% n = 31</td><td align="center" valign="middle" >AL &lt; 0.55% n = 19</td><td align="center" valign="middle" >AL &gt; 0.55% n = 31</td><td align="center" valign="middle" >AL &lt; 0.55% n = 19</td></tr><tr><td align="center" valign="middle" >On admission</td><td align="center" valign="middle" >110.7 &#177; 26.3*</td><td align="center" valign="middle" >83.2 &#177; 9.5</td><td align="center" valign="middle" >86.5 &#177; 66.4*</td><td align="center" valign="middle" >43.4 &#177; 20.3</td><td align="center" valign="middle" >82.1 &#177; 52.8*</td><td align="center" valign="middle" >43.6 &#177; 20.2</td></tr><tr><td align="center" valign="middle" >Day 03 from admission</td><td align="center" valign="middle" >145.2 &#177; 31.1*</td><td align="center" valign="middle" >102.8 &#177; 23.8</td><td align="center" valign="middle" >182.4 &#177; 167.1*</td><td align="center" valign="middle" >74.5 &#177; 36.1</td><td align="center" valign="middle" >152.0 &#177; 159.4*</td><td align="center" valign="middle" >78.3 &#177; 27.8</td></tr><tr><td align="center" valign="middle" >Day 05 from admission</td><td align="center" valign="middle" >130.6 &#177; 26.3*</td><td align="center" valign="middle" >96 &#177; 21.9</td><td align="center" valign="middle" >110.4 &#177; 81.0*</td><td align="center" valign="middle" >60.7 &#177; 23.4</td><td align="center" valign="middle" >105.0 &#177; 106.0*</td><td align="center" valign="middle" >65.1 &#177; 23.9</td></tr></tbody></table></table-wrap><p>*GR, AST and ALT levels of on admission, day 3 and day 5 from admission were significantly high when on admission AL &gt; 0.55%.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The sensitivity, specificity and cut of values of GR, AST and ALT levels to predict severity of dengue fever in relation to atypical lymphocyte level</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Biochemical parameters</th><th align="center" valign="middle" >Area under the curve (AUC)</th><th align="center" valign="middle" >Sensitivity (%)</th><th align="center" valign="middle" >Specificity (%)</th><th align="center" valign="middle" >Cut off values (IU/L)</th></tr></thead><tr><td align="center" valign="middle"  colspan="5"  >GR</td></tr><tr><td align="center" valign="middle" >On admission</td><td align="center" valign="middle" >0.884 (95%, CI = 79% - 97.8%)</td><td align="center" valign="middle" >80.6</td><td align="center" valign="middle" >82.4</td><td align="center" valign="middle" >92.5</td></tr><tr><td align="center" valign="middle" >3<sup>rd</sup> day from admission</td><td align="center" valign="middle" >0.894 (95%, CI = 79% - 99.9%)</td><td align="center" valign="middle" >83.9</td><td align="center" valign="middle" >77.4</td><td align="center" valign="middle" >121.0</td></tr><tr><td align="center" valign="middle" >5<sup>th</sup> day from admission</td><td align="center" valign="middle" >0.896 (95%, CI = 76% - 99.9%)</td><td align="center" valign="middle" >96.8</td><td align="center" valign="middle" >64.7</td><td align="center" valign="middle" >100.3</td></tr><tr><td align="center" valign="middle"  colspan="5"  >AST</td></tr><tr><td align="center" valign="middle" >On admission</td><td align="center" valign="middle" >0.764 (95%, CI = 63% - 89.7%)</td><td align="center" valign="middle" >80.6</td><td align="center" valign="middle" >58.8</td><td align="center" valign="middle" >47.5</td></tr><tr><td align="center" valign="middle" >3<sup>rd</sup> day from admission</td><td align="center" valign="middle" >0.866 (95%, CI = 75.7% - 97.5%)</td><td align="center" valign="middle" >87.1</td><td align="center" valign="middle" >70.6</td><td align="center" valign="middle" >84.5</td></tr><tr><td align="center" valign="middle" >5<sup>th</sup> day from admission</td><td align="center" valign="middle" >0.777 (95%, CI = 64.4% - 91%)</td><td align="center" valign="middle" >77.4</td><td align="center" valign="middle" >41.2</td><td align="center" valign="middle" >66.5</td></tr><tr><td align="center" valign="middle"  colspan="5"  >ALT</td></tr><tr><td align="center" valign="middle" >On admission</td><td align="center" valign="middle" >0.775 (95%, CI = 64.6% - 90.4%)</td><td align="center" valign="middle" >77.4</td><td align="center" valign="middle" >58.8</td><td align="center" valign="middle" >47.9</td></tr><tr><td align="center" valign="middle" >3<sup>rd</sup> day from admission</td><td align="center" valign="middle" >0.815 (95%, CI = 69.2% - 93.8%)</td><td align="center" valign="middle" >77.4</td><td align="center" valign="middle" >70.6</td><td align="center" valign="middle" >93.5</td></tr><tr><td align="center" valign="middle" >5<sup>th</sup> day from admission</td><td align="center" valign="middle" >0.728 (95%, CI = 58.5% - 87%)</td><td align="center" valign="middle" >67.7</td><td align="center" valign="middle" >64.7</td><td align="center" valign="middle" >77.5</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Regression model to predict platelet level depending on admission variables</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="9"  >Coefficients</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"   rowspan="2"  >Model</td><td align="center" valign="middle"  colspan="2"  >Unstandardized Coefficients</td><td align="center" valign="middle" >Standardized Coefficients</td><td align="center" valign="middle"  rowspan="2"  >t</td><td align="center" valign="middle"  rowspan="2"  >Sig.</td><td align="center" valign="middle"  colspan="2"  >95.0% Confidence Interval for B</td></tr><tr><td align="center" valign="middle" >B</td><td align="center" valign="middle" >Std. Error</td><td align="center" valign="middle" >Beta</td><td align="center" valign="middle" >Lower Bound</td><td align="center" valign="middle" >Upper Bound</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >1</td><td align="center" valign="middle" >(Constant)</td><td align="center" valign="middle" >127,155.279</td><td align="center" valign="middle" >11,989.162</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10.606</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >102,976.829</td><td align="center" valign="middle" >151,333.729</td></tr><tr><td align="center" valign="middle" >GR*</td><td align="center" valign="middle" >−397.065</td><td align="center" valign="middle" >156.295</td><td align="center" valign="middle" >−0.383</td><td align="center" valign="middle" >−2.540</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >−712.264</td><td align="center" valign="middle" >−81.867</td></tr><tr><td align="center" valign="middle" >AST*</td><td align="center" valign="middle" >−31.010</td><td align="center" valign="middle" >61.032</td><td align="center" valign="middle" >−0.068</td><td align="center" valign="middle" >−0.508</td><td align="center" valign="middle" >0.614</td><td align="center" valign="middle" >−154.093</td><td align="center" valign="middle" >92.072</td></tr><tr><td align="center" valign="middle" >ALT*</td><td align="center" valign="middle" >5.842</td><td align="center" valign="middle" >26.431</td><td align="center" valign="middle" >0.029</td><td align="center" valign="middle" >0.221</td><td align="center" valign="middle" >0.826</td><td align="center" valign="middle" >−47.462</td><td align="center" valign="middle" >59.145</td></tr><tr><td align="center" valign="middle" >AL*</td><td align="center" valign="middle" >−32,315.973</td><td align="center" valign="middle" >9586.794</td><td align="center" valign="middle" >−0.431</td><td align="center" valign="middle" >−3.371</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >−51,649.587</td><td align="center" valign="middle" >−12,982.359</td></tr></tbody></table></table-wrap><p>Dependent Variable: Platelet level – day 3 from admission. *on admission variables. Regression model; Day 3 Platelet level = 127,155.3 − 383 * GR − 0.431 * AL).</p></sec><sec id="s4"><title>4. Discussion</title><p>This study was carried out to determine the predictive power of GR, liver transaminases, and AL% on prediction severity and thrombocytopenia level in dengue viral infection. A previous study has observed a higher level of AL count among dengue/dengue hemorrhagic fever patients compared to patients with dengue like syndrome [<xref ref-type="bibr" rid="scirp.106829-ref11">11</xref>]. The percentage of AL count was higher among patients with respiratory compromise, hypotension, and bleeding symptoms. These results suggested that a higher level of AL% is associated with increased complications of dengue infection, leading to severe dengue and &gt;0.55% of AL count as a predictive marker for severity of dengue infection with higher sensitivity and specificity [<xref ref-type="bibr" rid="scirp.106829-ref12">12</xref>].</p><p>The present study showed that serum liver transaminases (AST and ALT) and GR levels correlated positively with AL%. All of these markers had high sensitivity and specificity to diagnose the severity of dengue infection along with AL%. Among these parameters percentage of AL and GR had a significant effect to predict platelet count of 3<sup>rd</sup> day from admission.</p><p>Even though there was no consistency in reported data on GPx and glutathione among dengue patients. Glutathione or glutathione derivatives are tested as a therapeutic agent to decrease oxidative stress in various diseases including dengue [<xref ref-type="bibr" rid="scirp.106829-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref23">23</xref>]. This probably would have contributed to maintain the reduced glutathione by reduction of oxidized glutathione. GR is responsible for supplying of reduced glutathione to control of cellular reactive oxygen species. Therefore, the recycling of oxidized glutathione is more essential to have effectively reduced glutathione for continued cell function [<xref ref-type="bibr" rid="scirp.106829-ref20">20</xref>]. Thus, the GR enzyme level has a potential being used as a predictive marker for early identification of dengue viral fever (3<sup>rd</sup> day from admission). The activity of GR may be reduced in day 5 from admission with decreasing of reactive oxygen species and severity of the disease. Furthermore, the multiple regression analysis proved that the GR level on admission and AL% appear to be as prominent predictive markers in association with a platelet count of day 3 of the infection.</p><p>Liver involvement of dengue fever and biochemical changes have discussed in various studies as very mild to severe liver disease [<xref ref-type="bibr" rid="scirp.106829-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref25">25</xref>]. Moderate elevation of liver enzymes of AST and ALT have also been reported (93 - 174 IU/L and 86 to 88.5 U/L) in different studies [<xref ref-type="bibr" rid="scirp.106829-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref27">27</xref>]. In the present study, 95% of dengue patients also had similar ranges of transaminases. The majority of the patients showed the high values of transaminases on day 03 from admission (5 - 6 days of onset of fever) in the present study. The studies also reported an increased level of liver enzymes correlated with the severity of the diseases [<xref ref-type="bibr" rid="scirp.106829-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.106829-ref29">29</xref>]. Similarly, we also reported observed on admission AST and ALT levels showed high sensitivity and specificity with the severity of dengue infection versus AL%.</p><p>These findings suggest that liver transaminases, GR and AL% play an important role in the determination of the severity of dengue infection. Furthermore, GR and AL% also can be used as predictive biomarkers in the determination of thrombocytopenia in dengue patients.</p><p>In summary, our study proposed combination of liver transaminases, GR, AL% with the degree of thrombocytopaenia with high sensitivity and specificity biomarkers as a profile test in early diagnosis of severity of dengue infection. This is the first study reported on the early diagnosis and prediction of thrombocytopenia in acute dengue viral infection. Further investigations are needed to elucidate the changes and association of total antioxidant capacity to predict severity of dengue fever over the period of admission to discharge.</p></sec><sec id="s5"><title>Acknowledgements</title><p>This work was supported by Nawaloka Hospitals Research and Education Foundation, Nawaloka Hospitals PLC, Colombo, Sri Lanka (Grant number: NHREF/RG/17/04). Further, we would like to extend our gratitude to Dr. Inoka Uluwaduge, Department of Basic Sciences, University of Sri Jayewardenepura for her contribution in proof reading, the patients who consented to be part of this study, and the staff at Nawaloka Haematology and Chemical Pathology Laboratories for their assistance.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><sec id="s7"><title>Cite this paper</title><p>Bandara, S., Chandrasena, L.G., Peiris, H., Abesuriya, V., De Silva, A., De Mel, C., De Mel, S. and Seneviratne, S.L. (2021) Glutathione Reductase, Liver Transaminases and Atypical Lymphocytes Count as Early Predictive Biomarkers in Diagnosis of Thrombocytopenia in Dengue Viral Infection. Journal of Biosciences and Medicines, 9, 119-130. https://doi.org/10.4236/jbm.2021.91010</p></sec></body><back><ref-list><title>References</title><ref id="scirp.106829-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kalayanarooj, S., Vaughn, D.W., Nimmannitya, S., Green, S., Suntayakorn, S., et al. (1997) Early Clinical and Laboratory Indicators of Acute Dengue Illness. The Journal of Infectious Diseases, 176, 313-321. https://doi.org/10.1086/514047</mixed-citation></ref><ref id="scirp.106829-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Trung, D.T., Thao, L.T.T., Hien, T.T., Hung, N.T., Vinh, N.N., et al. (2010) Liver Involvement Associated with Dengue Infection in Adults in Vietnam. The American Journal of Tropical Medicine and Hygiene, 83, 774-780. https://doi.org/10.4269/ajtmh.2010.10-0090</mixed-citation></ref><ref id="scirp.106829-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Souza, L.J., Alves, J.G., Nogueira, R.M.R., Gicovate Neto, C., Bastos, D.A., et al. (2004) Aminotransferase Changes and Acute Hepatitis in Patients with Dengue Fever: Analysis of 1,585 Cases. Brazilian Journal of Infectious Diseases, 8, 156-163. https://doi.org/10.1590/S1413-86702004000200006</mixed-citation></ref><ref id="scirp.106829-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Parkash, O., Almas, A., Jafri, S.M., Hamid, S., Akhtar, J., et al. (2010) Severity of Acute Hepatitis and Its Outcome in Patients with Dengue Fever in a Tertiary Care Hospital Karachi, Pakistan (South Asia). BMC Gastroenterology, 10, 43. https://doi.org/10.1186/1471-230X-10-43</mixed-citation></ref><ref id="scirp.106829-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Roy, A., Sarkar, D., Chakraborty, S., Chaudhuri, J. and Ghosh, P. (2013) Profile of Hepatic Involvement by Dengue Virus in Dengue Infected Children. North American Journal of Medical Sciences, 5, 480-485. https://doi.org/10.4103/1947-2714.117313</mixed-citation></ref><ref id="scirp.106829-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bandyopadhyay, D., Chattaraj, S., Hajra, A., Mukhopadhyay, S. and Ganesan, V. (2016) A Study on Spectrum of Hepatobiliary Dysfunctions and Pattern of Liver Involvement in Dengue Infection. Journal of Clinical and Diagnostic Research, 10, OC21-OC26. https://doi.org/10.7860/JCDR/2016/16946.7784</mixed-citation></ref><ref id="scirp.106829-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kumarasena, R.S., Mananjala, S.S., Sivaraman, K., De Silva, A.P., Dassanayake, A.S., et al. (2010) Intravenous N-Acetylcysteine in Dengue-Associated Acute Liver Failure. Hepatology International, 4, 533-534. https://doi.org/10.1007/s12072-010-9176-4</mixed-citation></ref><ref id="scirp.106829-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Snyder, A.H., McPherson, M.E., Hunt, J.F., Johnson, M., Stamler, J.S. and Gaston, B. (2002) Acute Effects of Aerosolized S-Nitrosoglutathione in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 165, 922-926. https://doi.org/10.1164/ajrccm.165.7.2105032</mixed-citation></ref><ref id="scirp.106829-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cacciatore, I., Cornacchia, C., Pinnen, F., Mollica, A. and Di Stefano, A. (2010) Pro Drug Approach for Increasing Cellular Glutathione Levels. Molecules, 15, 1242-1264. https://doi.org/10.3390/molecules15031242</mixed-citation></ref><ref id="scirp.106829-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Limphong, P., Pieper, J., Liu, Q., Rodesch, C.K., et al. (2012) Glutathion Dependent Reductive Stress Triggers Mitochondrial Oxidation and Cytotoxicity. The FASEB Journal, 26, 1442-1451. https://doi.org/10.1096/fj.11-199869</mixed-citation></ref><ref id="scirp.106829-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Franca, R.F., Zucoloto, S. and da Fonseca, B.A. (2010) A BALB/c Mouse Model Shows That Liver Involvement in Dengue Disease Is Immune-Mediated. Experimental and Molecular Pathology, 89, 321-326. https://doi.org/10.1016/j.yexmp.2010.07.007</mixed-citation></ref><ref id="scirp.106829-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fernando, S., Wijewickrama, A., Gomes, L., Punchihewa, C.T., Madusanka, S.D.P., et al. (2016) Patterns and Causes of Liver Involvement in Acute Dengue Infection. BMC Infectious Diseases, 16, 319. https://doi.org/10.1186/s12879-016-1656-2</mixed-citation></ref><ref id="scirp.106829-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chandrasena, L.G., Peiris, H., Kamani, J., Wanigasuriya, P., Jayaratne, S.D., et al. (2014) Antioxidants in Patients with Dengue Viral Infection. The Southeast Asian Journal of Tropical Medicine and Public Health, 45, 1015-1022.</mixed-citation></ref><ref id="scirp.106829-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Rajendiran, S., Lakshamanappa, H.S., Zachariah, B. and Nambiar, S. (2008) Desialylation of Plasma Proteins in Severe Dengue Infection: Possible Role of Oxidative Stress. The American Journal of Tropical Medicine and Hygiene, 79, 372-377. https://doi.org/10.4269/ajtmh.2008.79.372</mixed-citation></ref><ref id="scirp.106829-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Nasirudeen, A.M.A., Wong, H.H., Thien, P., Xu, S., Lam, K.P., et al. (2011) RIG-I, MDA5 and TLR3 Synergistically Play an Important Role in Restriction of Dengue Virus Infection. PLOS Neglected Tropical Diseases, 5, e926. https://doi.org/10.1371/journal.pntd.0000926</mixed-citation></ref><ref id="scirp.106829-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Soundravally, R., Hoti, S.L., Patil, S.A., Cleetus, C.C., Zachariah, B., et al. (2014) Association between Proinflammatory Cytokines and Lipid Peroxidation in Patients with Severe Dengue Disease around Defervescence. International Journal of Infectious Diseases, 18, 68-72. https://doi.org/10.1016/j.ijid.2013.09.022</mixed-citation></ref><ref id="scirp.106829-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Abeysuriya, V., Choong, C.S.H., Thilakawardana, B.U., de Mel, P., Shalindi, M., de Mel, C., et al. (2020) The Atypical Lymphocyte Count: A Novel Predictive Factor for Severe Thrombocytopenia Related to Dengue. Transactions of the Royal Society of Tropical Medicine and Hygiene, 114, 424-432. https://doi.org/10.1093/trstmh/trz128</mixed-citation></ref><ref id="scirp.106829-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Clarice, C.S.H., Abeysuriya, V., de Mel, S., Thilakawardana, B.U., de Mel, P., de Mel, C., et al. (2019) Atypical Lymphocyte Count Correlates with the Severity of Dengue Infection. PLoS ONE, 14, e0215061. https://doi.org/10.1371/journal.pone.0215061</mixed-citation></ref><ref id="scirp.106829-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Jampangern, W., Vongthoung, K., Jittmittraphap, A., Worapongpaiboon, S., Limkittikul, K., et al. (2007) Characterization of Atypical Lymphocytes and Immunophenotypes of Lymphocytes in Patients with Dengue Virus Infection. Asian Pacific Journal of Allergy and Immunology, 25, 27-36.</mixed-citation></ref><ref id="scirp.106829-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Datta, L. and Menon, M.P. (2017) Plasmacytoid Lymphocytes: A Clue to Dengue Diagnosis. Blood, 129, 2202. https://doi.org/10.1182/blood-2017-01-762500</mixed-citation></ref><ref id="scirp.106829-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">St John, A.L., Abraham, S.N. and Gubler, D.J. (2013) Barriers to Preclinical Investigations of Anti-Dengue Immunity and Dengue Pathogenesis. Nature Reviews Microbiology, 11, 420-426. https://doi.org/10.1038/nrmicro3030</mixed-citation></ref><ref id="scirp.106829-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Tissera, H., Rathore, A.P., Leong, W.Y., Pike, B.L., Warkentien, T.E., et al. (2017) Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. The Journal of Infectious Diseases, 216, 1112-1121. https://doi.org/10.1093/infdis/jix447</mixed-citation></ref><ref id="scirp.106829-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chandrasena, L., De Silva, A., De Mel, C., Peiris, H., Abesuriya, V., De Mel, S., Seneviratne, S. and Bandara, S. (2019) Glutathione Enzymes and Liver Injury in Acute Dengue Viral Infection. Journal of Biosciences and Medicines, 7, 61-71. https://doi.org/10.4236/jbm.2019.710006</mixed-citation></ref><ref id="scirp.106829-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Villar-Centeno, L.A., Díaz-Quijano, F.A. and Martínez-Vega, R.A. (2008) Biochemical Alterations as Markers of Dengue Hemorrhagic Fever. The American Journal of Tropical Medicine and Hygiene, 78, 370-374. https://doi.org/10.4269/ajtmh.2008.78.370</mixed-citation></ref><ref id="scirp.106829-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2009) Dengue Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/44188</mixed-citation></ref><ref id="scirp.106829-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gubler, D.J. (1998) Dengue and Dengue Hemorrhagic Fever. Clinical Microbiology Reviews, 11, 480-496. https://doi.org/10.1128/CMR.11.3.480</mixed-citation></ref><ref id="scirp.106829-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Huy, N.T., Van Giang, T., Thuy, D.H., Kikuchi, M., Hien, T.T., et al. (2013) Factors Associated with Dengue Shock Syndrome: A Systematic Review and Meta-Analysis. PLOS Neglected Tropical Diseases, 7, e2412. https://doi.org/10.1371/journal.pntd.0002412</mixed-citation></ref><ref id="scirp.106829-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mangold, K.A. and Reynolds, S.L. (2013) A Review of Dengue Fever: A Resurging Tropical Disease. Pediatric Emergency Care, 29, 665-669. https://doi.org/10.1097/PEC.0b013e31828ed30e</mixed-citation></ref><ref id="scirp.106829-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., et al. (2013) The Global Distribution and Burden of Dengue. Nature, 496, 504-507. https://doi.org/10.1038/nature12060</mixed-citation></ref></ref-list></back></article>